Literature DB >> 11971749

Transglutamines and endocrine system (minireview).

M Dvorcakova1, D Macejova, V Pallet, P Higueret, M-P Vasson, E Rock, J Brtko.   

Abstract

Transglutaminases catalyze the posttranslation modification of proteins by catalyzing Ca2+ dependent acyl-transfer reaction resulting in the formation of new g-amide bonds between g-carboxamide groups of peptide-bound glutamine residues and various primary amines. Such glutamine residue serves as acyl-donor and the most common acyl-acceptors are e-amino groups of peptide-bound lysine residues or primary amino groups of some naturally occurring polyamines, like putrescine or spermidine. The active site of cysteine reacts first with the g-carboxamide group of glutamine residue to form the acyl-enzyme intermediate under the release of ammonia. In the second step, the complex reacts with a primary amine to form an isopeptide bond and liberate the reactivated enzyme. The presence of transglutaminases has been observed in various endocrine glands such as human pituitary, which was investigated by immunohistochemical methods using specific antibodies. A significant increase in the expression and activity of tissue transglutaminase was observed during involution of thymus. In the genital tract of the male rat two different forms of the enzyme transglutaminase could be identified and characterized. the presence of p53 and tissues transglutaminase gene expressions in human normal and pathologic adrenal tissues. The Ca2+-responsive enzyme transglutaminase, which catalyzes the cross-bridging of proteins, was found in pancreatic islet cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971749

Source DB:  PubMed          Journal:  Endocr Regul        ISSN: 1210-0668


  2 in total

1.  Enteropathy precedes type 1 diabetes in the BB rat.

Authors:  S Graham; P Courtois; W J Malaisse; J Rozing; F W Scott; A Mc I Mowat
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

2.  Screening for celiac disease in poorly controlled type 2 diabetes mellitus: worth it or not?

Authors:  Muhammed Kizilgul; Ozgur Ozcelik; Selvihan Beysel; Hakan Akinci; Seyfullah Kan; Bekir Ucan; Mahmut Apaydin; Erman Cakal
Journal:  BMC Endocr Disord       Date:  2017-10-06       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.